SEC Tracker
Get the app
ABEO · XBRL financial data

Abeona Therapeutics financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (ABEO's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Revenue from contracts with customers0*0*—————4000*year only8,72011,380
Cost of goods and services sold————————488year only2,6964,177
Research and development7,1487,379*7,2079,2188,9418,994*9,9415,9434,2166,712*9,5555,021
Selling, general and administrative———8,6466,4047,678*9,78617,14919,31418,782*19,50215,835
General and administrative4,1565,830*7,1238,6466,4047,678*9,786——year only19,502—
Total operating expenses11,33413,209*14,33017,86415,34516,672*19,72723,192————
Operating income (loss)(11,334)(13,209)*(14,330)(17,864)(15,345)(16,672)*(19,727)(22,792)(24,018)(22,911)*(23,033)(13,653)
Interest expense105109*9521,0721,1021,082*998957901884*830696
Income tax expense (benefit)———————15,512(15,197)(215)*20*
Net income (loss)(11,836)(16,591)*(31,578)7,406(30,269)(9,293)*(12,029)108,833(5,161)(20,460)*(17,075)(20,191)
Earnings per share, basic USD per share(0.48)—(1.16)0.19(0.63)—(0.24)2.07(0.10)(0.37)*(0.30)(0.35)
Earnings per share, diluted USD per share(0.48)—(1.16)(0.26)(0.63)—(0.24)1.71(0.10)—(0.30)(0.35)
Weighted average shares, basic thousands of shares24,79825,669*27,31640,01048,08248,625*49,77952,52554,24355,192*56,62157,048
Weighted average shares, diluted thousands of shares24,79825,669*27,31651,22748,08237,530*49,77966,64154,243—56,62157,048

Balance sheet

CSV

Fiscal quarters (ABEO's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Cash and cash equivalents4,71214,47317,55834,42615,72623,35715,936163,53582,88478,43761,37456,229
Short-term investments49,04237,75344,78688,28293,97574,36368,21961,983124,233112,967106,89790,597
Accounts receivable—————————6,1476,2009,394
Inventory———————2,6864,8505,4936,0545,921
Prepaid and other current assets9637291,8111,2181,0051,1432,0112,0902,2091,2941,9511,942
Total current assets57,26455,73766,725125,904112,657100,85388,121232,262216,130204,906182,985164,578
Property and equipment, net3,9993,5333,7673,9754,0584,4306,9479,48910,3389,92110,56410,152
Right-of-use asset4,6854,4554,2224,0243,7893,5524,2394,1444,0863,9624,1183,950
Total assets66,08764,00274,828134,003120,592108,93199,364246,233231,095219,570198,494179,507
Accounts payable2,5921,8583,3623,0992,7893,4415,0187,3375,9277,8894,0712,994
Accrued liabilities3,9725,9852,7914,9245,2106,3333,8875,4956,8888,4675,3687,197
Current portion of long-term debt———2,2224,4445,9268,1485,5568,88912,22213,33313,333
Total current liabilities8,41213,42211,88916,84318,42216,58717,98334,51722,18029,57031,04624,806
Long-term debt——18,07916,13314,20613,03711,13814,00510,8627,8134,7541,655
Lease liability, non-current4,0434,4024,0463,0183,4023,2624,0783,9784,2544,0693,8143,604
Total liabilities44,04949,17683,70960,76274,81964,90057,96882,65759,86260,35453,55551,449
Accumulated deficit(732,933)(749,524)(781,102)(773,696)(803,965)(813,258)(825,287)(716,454)(721,615)(742,075)(759,150)(779,341)
Total stockholders' equity22,03814,826(8,881)73,24145,77344,03141,396163,576171,233159,216144,939128,058
Total liabilities and equity66,08764,00274,828134,003120,592108,93199,364246,233231,095219,570198,494179,507
Common shares outstanding (cover page) thousands of shares24,77327,35541,18643,31443,47148,53451,15751,27954,19157,04956,99557,184

Cash flows

CSV

Fiscal quarters (ABEO's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Net income (loss)(11,836)(16,591)*(31,578)7,406(30,269)(9,293)*(12,029)108,833(5,161)(20,460)*(17,075)(20,191)
Stock-based compensation1,557*1,514*1,5461,323*1,804*1,955*2,7012,830*2,689*2,559*2,9573,369*
Depreciation and amortization521*491*491487*487*539*534544*608*863*690665*
Net cash from operating activities(5,746)*(9,235)*(14,538)(12,684)*(12,234)*(16,559)*(18,402)(18,784)*(21,187)*(17,953)*(19,804)(17,496)*
Purchases of property and equipment44*37*725711*404*606*1,4012,901*2,520*1,153*935479*
Net cash from investing activities(18,743)*11,529*(7,817)(44,132)*(6,167)*18,876*4,213155,888*(64,627)*9,554*4,96315,686*
Proceeds from issuing common stock0*7,785*6,4173,545*0*5,513*6,79910,501*0*0*——
Proceeds from issuing equity—————year only10,500—————
Proceeds from long-term debt——20,0000*0*0*——————
Repayments of long-term debt——————————2,2223,334*
Net cash from financing activities22,976*7,467*25,44073,684*(299)*5,314*6,76810,495*5,163*3,614*(2,222)(3,335)*
Net change in cash(1,513)*9,761*3,08516,868*(18,700)*7,631*(7,421)147,599*(80,651)*(4,785)*(17,063)(5,145)*

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($K)Revenue, quarter ($K)Operating cash flow, quarter ($K)Shares outstandingRunwayQuarter
Abeona Therapeutics56,22911,380(17,496)*57.2M8.4 quarters 10-QJun 30, 2026
Tonix Pharmaceuticals Holding176,23213,544(42,243)*17.2M4.2 quarters 10-QJun 30, 2026
Vanda Pharmaceuticals61,93369,815(28,435)*60.5M1.7 quarters 10-QSep 30, 2026
Ocugen100,0511,488(12,198)*339.1M8.2 quarters 10-QJun 30, 2026
Mersana Therapeutics56,39111,009(3,192)*5.0M17.7 quarters 10-QSep 30, 2025
Atea Pharmaceuticals76,548not reported(37,084)*80.2M5.9 quarters 10-QJun 30, 2026
Standard Biotools267,48719,385(6,161)*394.8M21.6 quarters 10-QSep 30, 2026
Aquestive Therapeutics90,3497,557(7,046)*125.7M8.4 quarters 10-QSep 30, 2026
Merus367,49112,150(84,917)*75.8M7.5 quarters 10-QSep 30, 2025

Not investment advice. Not affiliated with the U.S. SEC.